Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus)

Tetsuro Konishi

Journal of Neurology Neurosurgery & Psychiatry · 2005 · 73 citations · 9 references

DOIFull text

Open access

Concepts

Abstract

Efficacy and safety of long term use of FK506 (2-4.5 mg/day) for a maximum of two years were evaluated in 12 patients with generalised myasthenia gravis (MG). At the end of the study, eight patients (67%) showed improvement in either MG score or Activities in Daily Living score, and prednisolone dosage could be reduced in seven patients (58%), with a mean reduction ratio of 37%. Long term use of FK506 for MG can be more effective than short term administration, with no serious side effects.

References

9